112 related articles for article (PubMed ID: 35025128)
1. ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.
Ollivier-Hourmand I; Repesse Y; Nahon P; Chaffaut C; Dao T; Nguyen TTN; Marcellin P; Roulot D; De Ledinghen V; Pol S; Guyader D; Archambeaud I; Zoulim F; Oberti F; Tran A; Bronowicki JP; D'Alteroche L; Ouzan D; Peron JM; Zarski JP; Bourliere M; Larrey D; Louvet A; Cales P; Abergel A; Mathurin P; Mallat A; Blanc JF; Nguyen-Khac E; Riachi G; Alric L; Serfaty L; Antonini T; Moreno C; Attali P; Thabut D; Pilette C; Grange JD; Silvain C; Carbonell N; Bernard-Chabert B; Goria O; Wartelle C; Moirand R; Christidis C; Perlemuter G; Ozenne V; Henrion J; Hillaire S; Di Martino V; Amiot X; Sutton A; Barget N; Chevret S; Ganne-Carrie N;
Liver Int; 2022 Jun; 42(6):1386-1400. PubMed ID: 35025128
[TBL] [Abstract][Full Text] [Related]
2. Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension.
Lisotti A; Azzaroli F; Cucchetti A; Buonfiglioli F; Cecinato P; Calvanese C; Simoni P; Arena R; Montagnani M; Golfieri R; Colecchia A; Festi D; Mazzella G
Liver Int; 2016 Sep; 36(9):1313-21. PubMed ID: 26786880
[TBL] [Abstract][Full Text] [Related]
3. Portal hypertensive colopathy in patients with liver cirrhosis.
Ito K; Shiraki K; Sakai T; Yoshimura H; Nakano T
World J Gastroenterol; 2005 May; 11(20):3127-30. PubMed ID: 15918202
[TBL] [Abstract][Full Text] [Related]
4. Prognostic usefulness of ultrasonographic signs of portal hypertension in patients with child-pugh stage A liver cirrhosis.
Macías-Rodríguez MA; Rendón-Unceta P; Martínez-Sierra MC; Teyssiere-Blas I; Díaz-García F; Martín-Herrera L
Am J Gastroenterol; 1999 Dec; 94(12):3595-600. PubMed ID: 10606325
[TBL] [Abstract][Full Text] [Related]
5. Influence of Progenitor-Derived Regeneration Markers on Hepatitis C Virus-Related Cirrhosis Outcome (ANRS CO12 CirVir Cohort).
Wendum D; Layese R; Ganne-Carrié N; Bourcier V; Merabtene F; Cagnot C; Sauce E; Barget N; Bedossa P; Terris B; Selves J; Bioulac-Sage P; Sturm N; Sattonnet C; Nahon P; Roudot-Thoraval F; Ziol M;
Hepatology; 2018 Oct; 68(4):1534-1548. PubMed ID: 29637581
[TBL] [Abstract][Full Text] [Related]
6. Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.
Brichler S; Nahon P; Zoulim F; Layese R; Bourcier V; Audureau E; Sutton A; Letouze E; Cagnot C; Marcellin P; Guyader D; Roulot D; Pol S; de Ledinghen V; Zarski JP; Calès P; Tran A; Peron JM; Mallat A; Riachi G; Grange JD; Blanc JF; Bacq Y; Ouzan D; Bronowicki JP; Mathurin P; Larrey D; Alric L; Attali P; Serfaty L; Pilette C; Bourlière M; Thabut D; Silvain C; Wartelle C; Zucman D; Christidis C; Roudot-Thoraval F; Ganne-Carrie N;
J Viral Hepat; 2019 Mar; 26(3):384-396. PubMed ID: 30380181
[TBL] [Abstract][Full Text] [Related]
7. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.
Thabut D; Bureau C; Layese R; Bourcier V; Hammouche M; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle-Bladou C; Dao T; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Sutton A; Audureau E; Roudot-Thoraval F; Nahon P;
Gastroenterology; 2019 Mar; 156(4):997-1009.e5. PubMed ID: 30768988
[TBL] [Abstract][Full Text] [Related]
8. Natural history of compensated viral B and D cirrhosis.
Gheorghe L; Iacob S; Simionov I; Vadan R; Gheorghe C; Iacob R; Parvulescu I; Constantinescu I
Rom J Gastroenterol; 2005 Dec; 14(4):329-35. PubMed ID: 16400347
[TBL] [Abstract][Full Text] [Related]
9. [Effects of primary preventive treatment under endoscope for esophageal and gastric varices on bleeding rate and its relevant factors].
Wang YL; Han J; Ma XM; Liu TT; Qi XB; Han B; Zhang HJ; Zhang WH
Zhonghua Gan Zang Bing Za Zhi; 2022 Apr; 30(4):407-412. PubMed ID: 35545566
[No Abstract] [Full Text] [Related]
10. Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension.
Garcia-Tsao G; Bosch J; Kayali Z; Harrison SA; Abdelmalek MF; Lawitz E; Satapathy SK; Ghabril M; Shiffman ML; Younes ZH; Thuluvath PJ; Berzigotti A; Albillos A; Robinson JM; Hagerty DT; Chan JL; Sanyal AJ;
J Hepatol; 2020 May; 72(5):885-895. PubMed ID: 31870950
[TBL] [Abstract][Full Text] [Related]
11. Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).
Trinchet JC; Bourcier V; Chaffaut C; Ait Ahmed M; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Buffet C; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Thiefin G; Hillaire S; Di Martino V; Nahon P; Chevret S;
Hepatology; 2015 Sep; 62(3):737-50. PubMed ID: 25678021
[TBL] [Abstract][Full Text] [Related]
12. Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).
Nahon P; Lescat M; Layese R; Bourcier V; Talmat N; Allam S; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Goria O; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Benhamou Y; Pilette C; Silvain C; Christidis C; Capron D; Bernard-Chabert B; Hillaire S; Di Martino V; Trinchet JC; Moreau R; Roudot-Thoraval F;
Gut; 2017 Feb; 66(2):330-341. PubMed ID: 26511797
[TBL] [Abstract][Full Text] [Related]
13. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial.
Lv Y; Yang Z; Liu L; Li K; He C; Wang Z; Bai W; Guo W; Yu T; Yuan X; Zhang H; Xie H; Yao L; Wang J; Li T; Wang Q; Chen H; Wang E; Xia D; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Cai H; Xia J; Yin Z; Wu K; Fan D; Han G;
Lancet Gastroenterol Hepatol; 2019 Aug; 4(8):587-598. PubMed ID: 31153882
[TBL] [Abstract][Full Text] [Related]
14. Emricasan to prevent new decompensation in patients with NASH-related decompensated cirrhosis.
Frenette C; Kayali Z; Mena E; Mantry PS; Lucas KJ; Neff G; Rodriguez M; Thuluvath PJ; Weinberg E; Bhandari BR; Robinson J; Wedick N; Chan JL; Hagerty DT; Kowdley KV;
J Hepatol; 2021 Feb; 74(2):274-282. PubMed ID: 33038432
[TBL] [Abstract][Full Text] [Related]
15. [Clinical features of liver cirrhosis complicated by portal vein thrombosis and related risk factors].
Lin GS; Xu Q; Zhao SY; Zhang YX
Zhonghua Gan Zang Bing Za Zhi; 2016 Jul; 24(7):513-517. PubMed ID: 27784429
[No Abstract] [Full Text] [Related]
16. Long-term follow-up study of adult patients with non-cirrhotic obstruction of the portal system: comparison with cirrhotic patients.
Merkel C; Bolognesi M; Bellon S; Sacerdoti D; Bianco S; Amodio P; Gatta A
J Hepatol; 1992 Jul; 15(3):299-303. PubMed ID: 1447495
[TBL] [Abstract][Full Text] [Related]
17. Natural history of patients with non cirrhotic portal hypertension: Comparison with patients with compensated cirrhosis.
Gioia S; Nardelli S; Pasquale C; Pentassuglio I; Nicoletti V; Aprile F; Merli M; Riggio O
Dig Liver Dis; 2018 Aug; 50(8):839-844. PubMed ID: 29429910
[TBL] [Abstract][Full Text] [Related]
18. Long-term clinical outcomes in patients with viral hepatitis related liver cirrhosis after transjugular intrahepatic portosystemic shunt treatment.
Teng D; Zuo H; Liu L; Dong J; Ding L
Virol J; 2018 Oct; 15(1):151. PubMed ID: 30285813
[TBL] [Abstract][Full Text] [Related]
19. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study.
Lv Y; Zuo L; Zhu X; Zhao J; Xue H; Jiang Z; Zhuge Y; Zhang C; Sun J; Ding P; Ren W; Li Y; Zhang K; Zhang W; He C; Zhong J; Peng Q; Ma F; Luo J; Zhang M; Wang G; Sun M; Dong J; Bai W; Guo W; Wang Q; Yuan X; Wang Z; Yu T; Luo B; Li X; Yuan J; Han N; Zhu Y; Niu J; Li K; Yin Z; Nie Y; Fan D; Han G
Gut; 2019 Jul; 68(7):1297-1310. PubMed ID: 30415233
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes following DAA therapy in patients with HCV-related cirrhosis depend on disease severity.
Krassenburg LAP; Maan R; Ramji A; Manns MP; Cornberg M; Wedemeyer H; de Knegt RJ; Hansen BE; Janssen HLA; de Man RA; Feld JJ; van der Meer AJ
J Hepatol; 2021 May; 74(5):1053-1063. PubMed ID: 33242501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
